You just read:

SCYNEXIS, Inc. Announces First Patient Dosed in Phase 3 Open-label Study Evaluating Oral Ibrexafungerp in Candida auris Infections (CARES)

News provided by

SCYNEXIS, Inc.

Oct 15, 2018, 09:26 ET